Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805057 | 1.00 | CYP1A2 (0.68) | CYP1A2CYP2A6ACHEALDH1A1TSHR | |
| SCHEMBL7824142 | 0.84 | CYP1A2 (0.68) | CYP1A2CYP2A6ACHEALDH1A1TSHR | |
| SCHEMBL29447796 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2A6ACHEALDH1A1TSHR | |
| SCHEMBL29363045 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2A6ACHEALDH1A1TSHR | |
| SCHEMBL30366540 | 0.83 | HPRT1 (0.46) | CYP1A2CYP2A6ACHEALDH1A1TSHR | |
| SCHEMBL161370 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2A6ACHEALDH1A1TSHR | |
| SCHEMBL6562728 | 0.83 | HPRT1 (0.46) | CYP1A2CYP2A6ACHEALDH1A1TSHR | |
| SCHEMBL23989159 | 0.77 | CYP1A2 (0.56) | CYP1A2CYP2A6ACHEALDH1A1TSHR | |
| SCHEMBL14596477 | 0.77 | CYP1A2 (0.44) | CYP1A2CYP2A6ACHEALDH1A1TSHR | |
| SCHEMBL19154180 | 0.75 | CYP1A2 (0.48) | CYP1A2CYP2A6ACHEALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125835-A1 | BLOCK COPOLYMER, METHOD FOR PRODUCING A BLOCK COPOLYMER, MEMBRANE, USE OF A MEMBRANE, AND METHOD FOR PRODUCING A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-11844273-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| WO-2023205719-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4209492-A1 | COMPOUND FOR TREATING THROMBOTIC DISEASES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-20230209856-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-29 | — | — | US | disclosed |
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-11563183-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-01-24 | — | — | US | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-02-15 | — | — | US | disclosed |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5807891-A | RETROVIRUSES | NOVARTIS AG (CH) | 1998-09-15 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0802173-A1 | Process for producing heterocylic aromatic amine or arylamine | Tosoh Corporation (JP) | 1997-10-22 | — | — | EP | disclosed |
| US-5663200-A | CARBAMOYL PEPTIDE DERIVATIVES AS VIRICIDES | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | CYP1A2 572/4885CYP2A6 1430/4885ACHE 450/4885 |
| US-11251376-B2 | Heterocyclic compound and organic light-emitting device including the same | LAGE3, DDT, AOC2 | CYP1A2 30/4885CYP2A6 897/4885ACHE 48/4885 |
| US-11563183-B2 | Heterocyclic compound and organic light-emitting device including the same | DDT, PPOX, LEF1 | CYP1A2 61/4885CYP2A6 1721/4885ACHE 213/4885 |
| US-11844273-B2 | Heterocyclic compound and organic light-emitting device including the same | DDT, PPOX, LEF1 | CYP1A2 61/4885CYP2A6 1721/4885ACHE 213/4885 |
| US-11566016-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | CYP1A2 4173/4885CYP2A6 4660/4885ACHE 650/4885 |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | CYP1A2 4173/4885CYP2A6 4660/4885ACHE 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.